Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Allogenic NK cell(Kian Immune Cell Company) in Glioblastoma Multiforme: NCT06687681 Clinical Landscape Report 2026
15 October 2026
NCT06687681 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Metastatic Triple-Negative Breast Carcinoma: NCT06690840 Clinical Landscape Report 2026
15 October 2026
NCT06690840 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
JY-231 in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: NCT06689917 Clinical Landscape Report 2026
15 October 2026
NCT06689917 clinical landscape for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Pegfilgrastim (Amgen) in Primary peritoneal carcinoma: NCT06690775 Clinical Landscape Report 2026
15 October 2026
NCT06690775 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WL-276 (Imunopharm) in Glioblastoma: NCT06691308 Clinical Landscape Report 2026
15 October 2026
NCT06691308 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BEBT-209 in Advanced Triple-Negative Breast Carcinoma: NCT06685796 Clinical Landscape Report 2026
15 October 2026
NCT06685796 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Toripalimab in Metastatic Clear Cell Renal Cell Carcinoma: NCT06690697 Clinical Landscape Report 2026
15 October 2026
NCT06690697 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Vorinostat in Neurofibrosarcoma: NCT06693284 Clinical Landscape Report 2026
15 October 2026
NCT06693284 clinical landscape for Neurofibrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanidatamab in Ovarian Cancer: NCT06695845 Clinical Landscape Report 2026
15 October 2026
NCT06695845 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride liposomal in Soft Tissue Sarcoma: NCT06694324 Clinical Landscape Report 2026
15 October 2026
NCT06694324 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Resiquimod Sulfate in Melanoma: NCT06697301 Clinical Landscape Report 2026
15 October 2026
NCT06697301 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sup-003 in High grade B-cell lymphoma: NCT06693973 Clinical Landscape Report 2026
15 October 2026
NCT06693973 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.